8 June 2024
A resoundingly negative vote by an advisory committee to the Food and Drug Administration – though not binding – has diminished the chances of winning full approval for MDMA to treat post-traumatic stress disorder.
A resoundingly negative vote by an advisory committee to the Food and Drug Administration – though not binding – has diminished the chances of winning full approval for MDMA to treat post-traumatic stress disorder.
Please use the contact form to get support. Thank you.